Karthik Kuppusamy Sells 1,760 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock

Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy sold 1,760 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $140.00, for a total transaction of $246,400.00. Following the completion of the sale, the senior vice president now owns 13,435 shares of the company’s stock, valued at approximately $1,880,900. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Quest Diagnostics Stock Performance

Shares of DGX opened at $137.38 on Friday. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $145.58. The company’s fifty day moving average is $130.33 and its 200-day moving average is $131.71. The firm has a market cap of $15.26 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The firm had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the business posted $2.04 earnings per share. The business’s quarterly revenue was up 1.7% on a year-over-year basis. Equities analysts expect that Quest Diagnostics Incorporated will post 8.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DGX has been the topic of several recent analyst reports. UBS Group boosted their target price on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Barclays upped their price target on Quest Diagnostics from $138.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. TheStreet lowered Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. Citigroup upped their target price on Quest Diagnostics from $135.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, Mizuho increased their price target on shares of Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $146.17.

Institutional Investors Weigh In On Quest Diagnostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NBC Securities Inc. bought a new position in shares of Quest Diagnostics in the third quarter valued at approximately $25,000. Altshuler Shaham Ltd bought a new position in Quest Diagnostics in the 4th quarter worth $26,000. VisionPoint Advisory Group LLC lifted its position in Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares during the last quarter. BKM Wealth Management LLC bought a new stake in Quest Diagnostics during the fourth quarter valued at about $29,000. Finally, Spartan Planning & Wealth Management acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at about $31,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.